| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Factor IX Activity w/reflex to Inhibitor
MessagePerformed at BUMCT, Advanced Coagulation
Test Code
F9RFLXINH
Alias/See Also
Factor 9
Preferred Specimen
3.2% Na Citrate Plasma, Blue Top
Minimum Volume
0.7 mL citrated plasma
Instructions
Light blue capped tubes (3.2% buffered sodium citrate) used for coagulation testing must be allowed to fill completely (after filling a small air space will normally be present). Short filled tubes will be rejected. Centrifuge within 1 hour of collection and complete testing within 4 hours of collection. If testing will not be completed within 4 hours, spin down, remove plasma, and spin plasma again. Pour off 2 aliquots into polypropylene plastic tube using a plastic transfer pipette. Freeze plasma at < -20°C
Transport Temperature
Frozen
Specimen Stability
| · Plasma stability - 4 hours at 2-8°C or 20°C, |
| · 2 weeks at -20°C - -80°C in a non-frost-free freezer |
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
| · clotted specimens |
| · underfilled or overfilled tube |
| · collection in 3.8% Citrate |
| · specimens collected in expired tubes |
| · serum samples |
| · specimen past stability |
| · thawed frozen samples |
| · Hemolyzed, Icteric and Lipemic samples |
Clinical Significance
The development of a circulating inhibitor is a serious complication of hemophilia. These inhibitors are highly specific antibodies that inactivate the corresponding clotting factor. Although inhibitors are seen most often in hemophilia A and B, and have also been reported in patients with vWD, congenital afibrinogenemia, hereditary deficiencies of factors II, V, VII, X, XI and XII
